From OHC, Specialists in Cancer and Blood Disorders
October 3, 2019
OHC is a leader in the development of a promising new treatment that is being studied in a new clinical trial for adult acute myeloid leukemia (AML).
AML is the most common type of acute leukemia in adults and can progress quickly if not treated immediately. Standard treatment options include chemotherapy, radiation therapy, and blood and marrow transplant.
As the region’s experts in blood and marrow transplants, OHC has seen tremendous success with blood and marrow transplants. Unfortunately, this treatment doesn’t always work for every patient. That’s why OHC continues to search for new treatment options.
“We have a new clinical trial underway that is evaluating a new medication to treat AML,” said E. Randolph Broun, MD, medical oncologist, hematologist, and blood and marrow transplant specialist who is the trial’s principal investigator. “If successful, this will provide another option for patients whose cancer didn’t respond to chemotherapy, radiation, or transplantation.”
The new treatment is an oral investigational drug called PTC299 that was originally developed to treat solid tumors, but showed promise with AML.
“For advanced cancer tumors to grow, they need new blood vessels,” Dr. Broun explained. “The tumors make a protein called vascular endothelial growth factor, or VEGF. This protein stimulates the formation of new blood vessels, which allows the tumor to grow. In pre-clinical trials, PTC299 was shown to decrease production of VEGF, and this, in turn, lowered the production of new blood vessel and therefore, slowed or stopped tumor growth.”
“In our Phase 1b clinical trial at OHC, we are looking at the use of PTC299 with the chemotherapy drug, docetaxel, to determine if it works better than docetaxel alone, and if patients are able to tolerate it. Results from the Phase 1a trial were significantly promising, so it has been advanced to this next level of testing,” he said.
“We’re pleased to offer this clinical trial here in our community so we can give our patients with AML early access to it,” said Dr. Broun.
If results are as promising as OHC hopes, it will offer another option, and a renewed sense of hope, for patients with AML.
“This is an exciting time to be involved in cancer research and clinical trials because scientific advancements are opening new doors for promising, revolutionizing cancer treatments almost daily. With the use of immunotherapy, inhibitors, and the ground-breaking CAR T-cell therapy, we’re on a path to outsmart cancer, with the ultimate goal of finding a cure,” Dr. Broun added.
To learn more about the PTC299 clinical trial (Refractory Acute Leukemias) at OHC, please visit www.ohcare.com/patient-resources/clinical-trials/available-trials/. For information about OHC, treatments or for a second opinion, please visit ohcare.com or call 1-800-710-4674.Comments (0)